← Back

China Resources Sanjiu Medical & Pharmaceutical Co Ltd

24.19-10.3%1Y · CNY

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. Its offerings include consumer health products (CHC) such as cold, flu, skin, gastrointestinal, cough, orthopedics, and pediatric drugs, plus dietary and nutritional supplements; prescription drugs in areas including anti-tumor, cardiovascular and cerebrovascular, digestive, orthopedics, pediatrics, and anti-infection; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services. Formerly Sanjiu Pharmaceutical Co., Ltd., it changed its name in February 2010, was incorporated in 1999, and is headquartered in Shenzhen, China, as a subsidiary of China Resources Pharmaceutical Group Limited.

Country
Price · split & dividend adjusted
News & notes moving 000999.CS
China
000999.CS▼4

China Resources Sanjiu's 2026 interim net profit was 1.671 billion yuan, down 7.96% year-on-year

China Resources Sanjiu released its 2026 interim report, with net profit attributable to the parent company of 1.671 billion yuan, a decrease of 7.96% compared with the same period last year. The company's total operating revenue was 15.014 billion yuan, up 1.37% year-on-year, achieving growth for five consecutive years. Net cash inflow from operating activities was 2.423 billion yuan, down 15.29% year-on-year. The company's latest asset-liability ratio was 29.92%, gross margin was 56.79%, ROE was 7.32%, and diluted earnings per share was 1.00 yuan.
000999.CS · Capital · Negative Net profit fell 7.96% year-on-year, missing prior performance.
Read original ↗
Jiemian·44dRead more →
000999.CS▼

Revised cold medicine label mandates no driving after use, testing China Resources Sanjiu's core product

The National Medical Products Administration issued Announcement No. 66, mandating a unified revision of the package insert for oral Ganmaoling preparations, explicitly stating that patients must not drive motor vehicles, vessels, or engage in high-altitude operations while taking the medicine. This revision extends the no-driving warning, previously only required for compound Ganmaoling preparations, to all oral Ganmaoling dosage forms, including granules, capsules, tablets, and teas. Relevant companies must complete the filing of the new package inserts by October 15, 2026, and replace the inserts and labels of already-shipped products within nine months after filing. China Resources Sanjiu, whose core product is 999 Ganmaoling, faces a test. Its 999 Ganmaoling Granules surpassed 2 billion yuan in sales in China's retail pharmacy terminal respiratory system Chinese patent medicine market in 2025, ranking first in the Chinese patent medicine cold and cough category for twelve consecutive years. China Resources Sanjiu's self-care business revenue in 2025 was approximately 15.111 billion yuan, down 14.67 percent year-on-year, and its attributable net profit in the first half of 2026 was about 1.672 billion yuan, down 7.9 percent year-on-year. Experts believe the new regulation will lead to structural sales diversion, and costs such as packaging material replacement cannot be underestimated.
000999.CS · Regulation · Negative New mandatory label warning for all oral Ganmaoling preparations, including 999 Ganmaoling, may reduce demand and increase compliance costs.
Read original ↗
北京商报·69dRead more →
000999.CS

China Resources Sanjiu Director Zhou Hui Resigns Multiple Posts Due to Retirement

China Resources Sanjiu announced that Zhou Hui has tendered her resignation as director, member of the board's strategic investment committee, vice president, general counsel, and chief compliance officer due to retirement. She will continue to serve as a director at the company's subsidiaries. In the first quarter of 2026, China Resources Sanjiu recorded revenue of 8.13 billion yuan and net profit attributable to the parent of 1.076 billion yuan.
000999.CS · · Neutral Director Zhou Hui resigns due to retirement; no material impact on operations or strategy.
Read original ↗
财中社·83dRead more →
000999.CS▼

China Resources Sanjiu 2026 First-Half Earnings Flash: Net Profit Attributable to Parent at 1.67 Billion Yuan, Down 7.90% Year-on-Year

China Resources Sanjiu released its 2026 first-half earnings flash, with net profit attributable to the parent of approximately 1.67 billion yuan, a year-on-year decline of 7.90%. The company achieved total operating revenue of about 15.01 billion yuan, up 1.37% year-on-year. Recurring net profit attributable to the parent was approximately 1.6 billion yuan, down 5.87% year-on-year. At the end of the reporting period, total assets stood at about 55.857 billion yuan, equity attributable to the parent was about 22.874 billion yuan, and net assets per share attributable to the parent were 13.74 yuan. The company stated it continues to promote a dual-wheel drive of innovation and brand, strengthening R&D innovation and intelligent digital empowerment. In the first quarter, the company achieved revenue of 8.13 billion yuan and net profit attributable to the parent of 1.076 billion yuan.
000999.CS · Capital · Negative Net profit attributable to parent fell 7.90% year-on-year, missing expectations.
Read original ↗
财中社·83dRead more →
000999.CS▲3

China Resources Sanjiu Participates in Project Winning Second Prize of 2025 National Science and Technology Progress Award

China Resources Sanjiu participated in the project "Construction and Application of an Innovative Technology System for Analyzing the Mechanism of Action of Traditional Chinese Medicine Centered on Functional Substances," which won the second prize of the 2025 National Science and Technology Progress Award. The project was led by Guangzhou University of Chinese Medicine and involved over twenty years of research, establishing an integrated full-chain technology platform covering functional substance discovery, biosynthesis, mechanism analysis, and clinical translation. As a participating unit, China Resources Sanjiu leveraged this technology system to complete pharmacodynamic substance basis research, quality marker discovery, process optimization, and standard upgrades for 999 Ganmaoling, Sanjiu Weitai, and several ancient classic formula compound preparations. This resulted in improved product quality stability and clinical efficacy reliability. The company stated that technological innovation is the core engine of its development, and it will continue to deepen collaborative innovation, accelerate the industrial translation of cutting-edge achievements in functional substance research of traditional Chinese medicine, and promote the high-quality development of the traditional Chinese medicine industry.
000999.CS · Technology · Positive Company participated in award-winning project for TCM mechanism analysis technology, improving product quality and clinical efficacy.
Read original ↗
中国证券报·87dRead more →